Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...

Goldman Sachs lowered the firm’s price target on Alkermes (ALKS) to $30 from $32 and keeps a Buy rating on the shares. The ...

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

During the last three months, 9 analysts shared their evaluations of Alkermes ALKS, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ...

Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at ...

Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

Alkermes is a biopharmaceutical company primarily involved in developing treatments for central nervous system disorders. Its current lineup includes schizophrenia treatment Aristada ...

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares. Alkermes reported Q3 revenues below consensus estimates but in ...

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. The investment bank said it is now “very confident ...